XNYS
EVMN
Market cap232mUSD
Oct 08, Last price
6.41USD
1D
3.05%
1Q
-51.48%
IPO
-65.18%
Name
Evommune Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
13m
+85.71%
Net income
-69m
L+3.09%
CFO
-76m
L+31.35%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
Key people
Benjamin McGraw
Chairman of the Board · since 2024
Janice Drew
Executive Vice President - Operations · since 2022
Hans Hofland
Senior Vice President - Research
Jeegar Patel
Chief Scientific Officer · since 2022
Chief Business and Legal Officer, Corporate Secretary, Chief Compliance Officer · since 2022
Chief Medical Officer, Director · since 2020
Francois Beaubien
Director · since 2024
Derek DiRocco
Independent Director · since 2024
Independent Director · since 2020
Independent Director Nominee · since 2024
Felice Weegen
Independent Director · since 2021
Luis Pena
President, Chief Executive Officer, Director
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |